GLP-1RA may have varying effects on cardiac structure in patients with ASCVD depending on BMI

GLP-1RA may have varying effects on cardiac structure in patients with ASCVD depending on BMI

BackgroundGlucagon-like peptide-1 receptor agonist(GLP-1RA) is commonly used in patients with cardiovascular disease due to its significant improvement in the prognosis of atherosclerotic cardiovascular disease (ASCVD). However, previous studies have primarily focused on obese patients, leaving unce...

Full description

Bibliographic Details
Main Authors: Ling Xu, Dan Zhu
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Endocrinology
Subjects:
GLP-1RA
cardiac remodeling
body mass index
weight loss
ASCVD
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2024.1355540/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2024.1355540/full

Similar Items